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Abstract
Two new cases of dilated cardiomyopathy
(DC) caused by dystrophinopathy are
reported. One patient, a 24 year old man,
had a family history of X linked DC, while
the other, a 52 year old man, had sporadic
disease. Each had abnormal dystrophin
immunostaining in muscle or cardiac
biopsy specimens, but neither had muscle
weakness. Serum creatine kinase activity
was raised only in the patient with familial
disease. Analysis of dystrophin gene mu-
tations showed a deletion of exons 48–49 in
the patient with familial DC and of exons
49–51 in the other. Dystrophin transcrip-
tion in cardiac tissue from the patient with
sporadic disease showed abundant expres-
sion, predominantly of the muscle iso-
form. This study, together with previous
reports, suggests that some patients with
DC have a dystrophinopathy that can be
diagnosed using a combination of bio-
chemical and genetic analyses.
(Heart 1997;78:608–612)
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Duchenne’s (DMD) and Becker’s muscular
dystrophies (BMD) are allelic X linked neuro-
muscular disorders. They result from muta-
tions in the dystrophin gene that, when severe
as in DMD (nonsense or out of frame
mutations), lead to lack of expression of the
sarcolemmal protein dystrophin.1 Up to one
third of all cases of DMD and BMD arise from
de novo mutations, so that a significant
proportion of aVected males have no family
history of the condition.1 2 The absence of dys-
trophin in DMD causes severe and progressive
muscle weakness, loss of ambulation before the
age of 13, and death in the late teens or early
twenties.3 BMD is a milder form of muscular
dystrophy in which individuals are ambulant
after the age of 16. These individuals usually
have in frame deletions and residual expression
of a partially functional dystrophin in the
muscle.3
Cardiac involvement is an integral part of
DMD and BMD.4–7 In rare instances, however,
patients can suVer from dilated cardiomyo-
pathy (DC) as the only manifestation of a dys-
trophinopathy. This has been now recognised
in families with typical X linked DC8–11 and in
patients with sporadic disease.12–14 Unlike
patients with DMD or BMD, these patients did
not have symptoms of muscle weakness and the
only sign of neuromuscular involvement was
raised serum creatine kinase (CK) activity.
Several patients had mutations clustered in the
5' end of the gene9 11 12; a region not aVected by
mutations usually found in DMD and BMD.
DC has also been reported in asymptomatic
female carriers of DMD and BMD.15
Two cases of familial (X linked) and sporadic
DC secondary to a dystrophinotrophy are
reported here.
Patients
The two patients described in this study origi-
nate from Italy. Ethical approval was obtained
from the committees of the two hospitals
involved in their assessment. Informed consent
was obtained from each patient.
PATIENT 1
The first patient, a 24 year old man, was
admitted in August 1991 after the recent onset
of dyspnoea with mild physical activity.DCwas
diagnosed (left ventricular end diastolic diam-
eter 73 mm; left ventricular end diastolic
volume 107 ml/mq; left ventricular ejection
fraction 27%) after exclusion of active myocar-
ditis by endomyocardial biopsy and coronary
artery disease by angiography. An electrocar-
diogram showed Q waves in the inferior and
posterior leads and incomplete right bundle
brunch block. Sustained ventricular arrhyth-
mias were detected after 24 hour Holter moni-
toring. Among the biochemical investigations,
constantly raised serum CK activity (MM iso-
form, ranging between 540 and 867 U/l,
normal < 200 U/l) was found. Neurological
investigation failed to show any weakness or
muscle wasting or hypertrophy. The patient
denied symptoms of neuromuscular involve-
ment such as cramps or myalgias associated
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with exercise. He improved following treat-
ment with digitalis, enalapril, and metoprolol
and remained in New York Heart Assocation
(NYHA) class I–II. During follow up the left
ventricular dimension slightly diminished (left
ventricular end diastolic diameter 70 mm),
although the systolic function remained signifi-
cantly depressed (left ventricular ejection frac-
tion 37%) with diVuse wall motion abnormali-
ties, more evident in the inferoposterior region.
Mild right ventricular dysfunction was ob-
served at radionuclide angiography (right ven-
tricular ejection fraction 35%). At the last
follow up (1996) the patient was in NYHA
class II with a peak consumption of oxygen of
14.4 ml/kg/min (anaerobic threshold 5.8 ml/
kg/min) and without evidence of electrical ven-
tricular instability with Holter monitoring or
during exercise.
Analysis of the pedigree disclosed a strong
family history of DC suggestive of an X linked
inheritance (fig 1). Individuals II:3, III:6, and
III:11 (fig 1) had been aVected by DC and died
at the ages of 36, 42, and 38, respectively.
Moreover, a maternal aunt (individual II:5, fig
1), an obligate carrier for the condition, also
died of DC at the age of 57. Interestingly, indi-
vidual III:8 had DMD and died because of res-
piratory complications at the age of 22. All
other aVected members did not have signs of
skeletal muscle involvement, at least as far as
could be assessed from their medical records
and questioning their relatives. A needle
muscle biopsy specimen from the propositus
(individual III:4, fig 1) was obtained to investi-
gate the possibility of an underlying dystrophi-
nopathy.
PATIENT 2
The second patient, a 52 year old man, died
shortly after cardiac transplantation in 1994.
He was employed in the chemical industry and
was physically active until the age of 50 when
he presented with the first symptoms of cardiac
failure. There was no family history of cardio-
vascular disease. The patient smoked 20
cigarettes daily and admitted moderate alcohol
intake until the age of 50, when he developed a
gastric peptic ulcer that eventually required
surgical excision. On examination, aged 52, he
was dyspnoeic at rest and a systolic murmur
was present over the mitral valve. There was an
additional third tone, but no raised jugular
venous pressure or peripheral oedema. His
liver was enlarged and neurological examin-
ation failed to show muscle atrophy or pseudo-
hypertrophy. His muscle strength was normal,
as was serum CK activity (84 U/l). Negative T
waves in leads V5–V6 were seen on the electro-
cardiogram. Echocardiography showed a di-
lated left ventricle (left ventricular end diastolic
diameter 70 mm, left ventricular ejection frac-
tion 20%). The right ventricle and both atria
were also dilated. Moderate mitral and tricus-
pidal valve regurgitation was also found. Right
heart catheterisation disclosed pulmonary hy-
pertension, (pulmonary artery pressure 68/
30 mm Hg, mean 42 mm Hg), and a reduced
cardiac index (2.0 l/min/m2). Despite medical
treatment with angiotensin converting enzyme
inhibitors, digitalis, and diuretics the patient
deteriorated clinically and he underwent car-
diac transplantation nine months later. In the
early postoperative period he suVered from
multiorgan failure and died shortly after.
Methods
IMMUNOHISTOCHEMICAL STUDY OF SKELETAL
AND CARDIAC MUSCLE
A cardiac biopsy specimen obtained at
cardiac transplantation, and a needle biopsy
specimen of skeletal muscle taken from patient
1 were immediately frozen in liquid nitrogen
cooled isopentane and stored at −70ºC or in
liquid nitrogen. The specimens were fully
processed for histological, histochemical, and
immunohistochemical examination.16 In par-
ticular, unfixed cryostat sections (6 µm) were
immunostained using a panel of six antidys-
trophin antibodies, including the monoclonal
antibody DYS1808 (Ylem, Italy), as already
described.17
DNA STUDIES
DNA was isolated from leucocytes by standard
methods.Multiplex DNA amplification of dys-
trophin exons was carried out according to
previously described techniques.18 19
REVERSE TRANSCRIPTION AND POLYMERASE
CHAIN REACTION
Total RNA20 was isolated from control frozen
skeletal muscle and heart and from the left
ventricle of patient 2. cDNA synthesis was
performed using random hexanucleotide prim-
ers, following the procedure already
described.21 22 Polymerase chain reaction was
performed using forward primers designed to
amplify the muscle, brain, and Purkinje cell
isoforms and an exon 6 reverse primer as
already described.21
Results
IMMUNOHISTOCHEMICAL ANALYSIS
The skeletal muscle biopsy specimen from the
propositus showed mild dystrophic changes,
characterised by an increase in internal nuclei
(12%), mild variability of fibre size with hypo-
trophic and hypertrophic fibres, and rare fibre
splittings in an otherwise well preserved
muscle. There were no signs of degeneration
or regeneration and only a marginal increase
in connective tissue. Immunohistochemistry
Figure 1 Pedigree of family with X linked cardiomyopathy. Open symbols, unaVected
individuals; closed circles, aVected individuals; barred symbols, deceased (number above is
age at death); dotted circles, obligate carriers; arrow, propositus.
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performed with the panel of antidystrophin
antibodies showed variability in the immunore-
action between adjacent fibres (fig 2), the level
of dystrophin expression being weaker than
control muscle (fig 2).
Skeletal muscle samples were not available
from patient 2. His cardiac biopsy specimen
showed significant fibrosis, separating indi-
vidual cardiomyocytes in some areas, and gross
variability of fibre size mainly due to hyper-
trophic cardiomyocytes. A few cardiac cells
undergoing degeneration were also seen. Im-
munostaining with antibodies directed towards
the N terminal, mid-rod, and C terminal
domain of dystrophin was strong and continu-
ous, although there was some variability
between adjacent fibres, mostly visible using N
terminal antibodies (fig 3). There was no stain-
ing, however, using the terminal rod domain
antibodies DYS-1808, suggesting the presence
of a mutation in the genomic region encoding
for this epitope (fig 3). Previous studies
indicate that such region exists between exons
49 and 51.23
Western blot analysis22 showed a slight
reduction in the amount of dystrophin expres-
sion with a small decrease in molecular weight
(fig 4).
Figure 2 Immunohistochemical staining of skeletal muscle with Dys-III N terminus antidystrophin antibodies.
(A) Normal muscle: all fibres equally and intensely stained (original magnification ×280). (B) Muscle from patient 1:
staining is weaker than control muscle, suggesting a dystrophinopathy (original magnification ×280).
Figure 3 Top, immunohistochemical staining of cardiac muscle from patient 2 using antidystrophin antibodies. Bottom, protein dystrophin and epitopes of
three of the antibodies used in the study. Top left, N terminus antidystrophin antibodies (Dys3) with a near normal reaction; top middle, no staining was
visible with mid-rod domain 1808 antidystrophin antibodies; top right, reduced staining with Dys2 C terminus antidystrophin antibodies (original
magnifications ×320).
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DYSTROPHIN GENE ANALYSIS
Multiplex ploymerase chain reaction deletion
study showed deletion of the central region of
dystrophin (data not shown). In the patient
with sporadic disease in frame deletion of
exons 49–51 was found, while the propositus of
the family with DC had a deletion of exons
48–49, which was subsequently confirmed in
the obligate carriers (II:1 and II:7).
TRANSCRIPTION STUDIES
Transcription of dystrophin muscle, brain, and
Purkinje cell isoforms from the heart of patient
2 resulted in a pattern of isoform expression
indistinguishable from that in control heart.
Expression of the muscle isoform was high,
while that of the brain was low. Purkinje cell
isoforms were not expressed (fig 5).
Discussion
Cardiac involvement is very common in DMD
and BMD. Almost all patients with DMD have
signs of cardiac involvement in the late stages of
their disease,5 while various authors have
reported an incidence of cardiac involvement
in patients with BMD of approximately
60–65%.5–7
Our group recently reported that the dys-
trophin gene is also involved in some patients
with X linked DC.9 11 Dystrophin expression
and transcription in these families showed that
dystrophin was absent in the heart but not in
skeletal muscle, thereby providing a biochemi-
cal explanation for severe cardiomyopa-
thy.11 21 24 The fact that several patients with X
linked DC carried unusual but similar muta-
tions in the extreme 5' end of the gene9 11 12
suggests a link between these mutations and
the prevalent cardiac involvement. In contrast,
there is still no information on the precise
prevalence of dystrophin abnormalities in a
population of patients with DC.The only study
that has addressed this issue was performed on
27 males with DC, but dystrophin deletion was
not found, suggesting that the frequency of
dystrophinopathy in the population of patients
with DC is probably low.25
Two further cases of DC without muscle
weakness due to a dystrophinopathy are
reported here. In each patient there was a dele-
tion in the central rod domain of dystrophin, a
region located in the dystrophin deletion “hot
spot”. Identical mutations are typically associ-
ated with mild BMD.2–26 The reason for the
lack of skeletal muscle involvement in our
patients with a “typical BMD deletion” is
unclear, but intriguing, especially considering
that the patient with sporadic disease had nor-
mal serum CK activity. The mechanism of car-
diac involvement in our patients is likely to be
diVerent from that in patients with mutations
in the 5' of the gene, in whom cardiac
expression of dystrophin could not be
found.11 24 Indeed, high levels of cardiac
dystrophin expression were seen in the patient
with sporadic disease with a deletion of exons
49–51 using both immunocytochemistry and
western blot analysis. Moreover, the transcrip-
tion pattern in this patient was indistinguish-
able from that seen in normal heart—that is,
prevalent expression of the muscle isoform
with lower expression of the brain isoform.21
Unfortunately, cardiac muscle was not avail-
able from the other patient with a deletion of
exons 48–49.
Various authors have reported a high inci-
dence of cardiac involvement in patients with
BMD with deletions involving exon 49, while
deletion of only exon 48 are less frequently
associated with a cardiomyopathy.7 27 28 It has
been proposed that intron 48 might contain
sequences relevant to the function of dys-
trophin in cardiac muscle. This intronic
sequence would be removed or preserved by an
intragenic deletion involving exon 48, depend-
ing on the break point within intron 48, while
any deletion encompassing both exons 48 and
49 would remove these sequences.7 28 Another
possibility is that exon 49 contains a domain
with an essential function for the heart. Recent
analysis of dystrophin has shown, for example,
the presence of a calcium binding domain
within the cysteine rich region,29 while a WW
domain, involved in mediating protein protein
interaction, is present in exons 62–64.30 Exon
49 is located in the central region of dys-
trophin, however, where the protein has an
organisation similar to that of the coiled coil
repeats of spectrin.31 Exon 49 is contained
entirely in repeat 1931 and therefore it seems
unlikely to have a structure that might account
for a specific and unique function in the heart.
We have no explanation as to why a cousin of
the patient in the family with DC was aVected
by DMD,while the three remaining individuals
had no signs of skeletal muscle involvement.
One possibility is that of a second mutation in
the dystrophin gene. Such an eventuality has
been reported,32 33 although it is rare. Unfortu-
nately, DNA or skeletal muscle was not
available from this patient.
Our results suggest that a deletion of the
dystrophin region involved in the cases re-
ported here can give rise not only to BMD, but
also to DC. Intriguingly, serum CK activities
can be normal, as highlighted by our patient
with sporadic disease. High serum CK activi-
Figure 4 Western blot
analysis of cardiac biopsy
from (A) control and
(B) patient 2, probed with
mid-rod antidystrophin
antibody (P6).22 Note
the slight reduction in
abundance and molecular
weight of dystrophin in the
patient (arrow).
Figure 5 Amplification of cDNA from normal cardiac
muscle (C) and the cardiac biopsy from patient 1 (252).
Dystrophin muscle isoform (M) was amplified as a 494
base pair fragment, the brain isoform (B) as 482 base pairs,
and the Purkinje cell isoform (P) as 503 base pairs. The
cardiac muscle biopsy from patient 1 showed transcription
of trace amount of isoform B and higher expression of
isoform M, but no expression of isoform P. The control
cardiac tissue showed an identical pattern of isoform
transcription with a trace amount of isoform B and high
expression of isoform M.Lane K,molecular weight marker.
Dystrophin in dilated cardiomyopathy 611
group.bmj.com on March 18, 2015 - Published by http://heart.bmj.com/Downloaded from 
ties are therefore not essential for suspecting
DC secondary to a dystrophinopathy.
In conclusion, two cases of DC secondary to
a dystrophin mutation are reported. The find-
ings suggest that involvement of dystrophin can
be responsible for idiopathic DC, although its
incidence is probably low.25 Combined genetic
and biochemical studies on a larger patient
population are needed to clarify the prevalence
of dystrophin abnormalities in patients with
DC.
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